Luminex Corporation Announces European Unveiling of its New Sample-to-Answer System at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) System's Innovative Design and Ease-of-Use Will Streamline Laboratory Workflow
AUSTIN, Texas, May 5, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced it will unveil its new sample-to-answer system for infectious disease testing, ARIES™ at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). ARIES' scalable throughput, easy to use design, and networked data management software will deliver rapid results with a simple workflow.
The five assay launch menu targeted for the ARIES system will include: Flu A/B and RSV, HSV 1&2, Norovirus and Clostridium difficile (C. diff). Future menu items will be announced at a later date.
"ARIES will revolutionize molecular diagnostic testing with a system that integrates seamlessly into the laboratory," said Russell W. Bradley, senior vice president, corporate development and global marketing. "Enabling laboratories to produce faster results, and better manage their QC and compliance requirements can increase service levels to hospitals and doctors for improved patient care."
The unveiling will take place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) May 11, 2014 at 11am CEST, booth #23. Russell W. Bradley will introduce the innovative sample-to-answer system, ARIES, and give a short demonstration.
The 24th European Congress of Clinical Microbiology and Infectious Diseases is taking place in Barcelona, Spain, 10 – 13 May, 2014. ESCMID's yearly congress attracts around 10,000 participants. The Program Committee will prepare a series of keynote lectures, symposia, educational workshops, and meet-the-expert sessions on parallel tracks, covering the entire field of infectious diseases and clinical microbiology.
About Luminex Corporation (NASDAQ: LMNX)
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
Luminex Media Contact
Mimi Torrington, 512.219.8020
Director of Marketing Communications
SOURCE Luminex Corporation